Should I buy Solventum (SOLV) stock or is it too late?

Solventum · Health Care · price $86

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Stifel — 68% of its targets hit on this sector (304 calls tested). It aims for $100 (+16 %), call made on August 7, 2026, maturing on August 7, 2027 (68 d ago).

The 4 reliable analysts $101+16 %

The 4 other firms $91+5.4 %

How to read it: the 4 reliable firms are not filtered by optimism — 4 aim above the price, 0 below, hence their $101 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

In short — Should you invest in Solventum? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $101, i.e. +16%), and the most reliable on SOLV targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
Median price target $101, i.e. +16% from the current price ($86).
The most reliable firm on SOLV, Piper Sandler (100% hit rate, 2 scored calls), targets $105 (call made on August 6, 2026, maturing on August 6, 2027) (+22%) in its most recent call, and $98 (call made on November 7, 2025, maturing on November 7, 2026) (+14%) in the one coming due soonest.
Reasonable valuation (P/E ~10) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 8 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on SOLV

Median target $101 (+16%) · 8 ratings · Buy consensus

Strong Buy00%

Buy675%

Hold225%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Solventum now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $101 (+16%), and Piper Sandler (most reliable on SOLV, 100%) targets $105. Weigh that against valuation (P/E ~10). This is not personalized advice.

Is it too late to invest in Solventum?

Not according to analysts: the median target ($101) is still +16% above the current price ($86) (most reliable on SOLV: Piper Sandler, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Solventum still worth investing in?

It depends on the gap between the price ($86) and its estimated value: analysts target $101 on median (+16%), with 75% buys (most reliable on SOLV: Piper Sandler, 100%). Cross-check with their real reliability on SOLV and the cautions above. Information, not advice.

What's the main risk in buying SOLV?

The consensus is not unanimous: of 8 ratings, 2 are neutral.

→ Go deeper: the full Solventum profile (consensus, analyst reliability, price target, performance).